Sponsored diagnostic testing programs for APOL1-Mediated Kidney Disease (AMKD)
AMKD is caused by specific APOL1 risk variants (G1 or G2) that increase susceptibility to kidney damage. It primarily affects individuals of African ancestry and is associated with higher rates of chronic kidney disease, rapid decline in kidney function, and progression to kidney failure. Genetic testing is the only way to confirm APOL1 high-risk genotypes and can help inform prognosis, monitoring, and eligibility for emerging therapies.
1 program found for APOL1-Mediated Kidney Disease (AMKD)
This program offers no-cost Renasight™ testing for eligible patients of African ancestry with chronic kidney disease. It supports early identification of APOL1 risk variants associated with APOL1-mediated kidney disease (AMKD). Providers can use results to inform diagnosis, guide management decisions, and determine whether genetic factors may underlie renal decline.
